JA
John Aballi
President and CEODirector

John Aballi insider trades: Exagen (XGN) stock buys and sales

President and CEO, Exagen Last trade Oct 16, 2026 15 Form 4 filings
$368K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2022
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where John reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 16, 2026XGN↓ Sell$270K
Mar 3, 2026XGN↓ Sell$57K
Feb 24, 2026XGN↓ Sell$41K
Oct 16, 2025XGN↓ Sell$376K
Nov 14, 2024XGN↑ Buy$68K
May 16, 2024XGN↑ Buy$78K
Oct 17, 2023XGN↓ Sell$59K
Dec 8, 2022XGN↑ Buy$241K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other XGN insiders

Open-market trades in the last 12 months

About John Aballi's insider trades

John Aballi is President and CEO at Exagen (XGN). Since Dec 8, 2022, John has reported 3 open-market purchases worth $387K and 5 sales worth $802K on SEC Form 4. In the last 12 months: 3 sales ($368K).

Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.